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Abstract: Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally re-
model the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and 
human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix deg-
radation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Re-
cently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor block-
ers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage 
of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, 
propagation, and therapeutics of cerebral ischemic diseases.  
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1. INTRODUCTION 
  Matrix metalloproteinases (MMPs) are a family of zinc- 
and  calcium-dependent  proteolytic  enzymes  that  normally 
remodel the extracellular matrix. MMPs cleave most compo-
nents  of  the  extracellular  matrix  including  fibronection, 
laminin, proteoglycans and type IV collagen [56]. An over-
expression of MMPs followed by accelerated matrix degra-
dation is associated with several pathologies including can-
cer cell invasion and metastasis, the loss of cartilage in os-
teoarthritis,  rheumatoid  arthritis,  cardiovascular  diseases, 
acute  lung  injury,  chronic  obstructive  pulmonary  disease, 
eye and skin diseases and periodontitis [15]. 
  Among  MMPs,  matrix  metalloproteinase-9  (MMP-9) 
/gelatinase B has been proved to play an important role in 
wound healing, angiogenesis, inflammation, tumor invasion 
and metastasis [51]. And during the last decade, an abnormal 
expression of MMP-9 has been shown to play a deleterious 
role in brain injury in both animal models of cerebral ische-
mia and human stroke. Furthermore, MMP-9 knockout mod-
els or treatment with MMP tissue inhibitors, synthetic MMP 
inhibitors and MMP neutralizing antibodies have been shown 
to  protect  blood-brain  barrier  (BBB),  reduce  vaso-genic 
edema formation and infarct size after cerebral ischemia [1, 
2, 38, 49, 52, 58, 71]. These suggest that MMP-9 might be 
an important clinical target for the therapy of human cerebral 
ischemia. Furthermore, several experiments have been car-
ried out to investigate the relationship between some medi-
cines and MMP-9 expression levels. Researchers expect to 
find some new drugs for the treatment of ischemic diseases. 
2.  THE  MOLECULAR  STRUCTURE  AND  PHYSIO-
LOGICAL FUNCTION OF MMP-9 
  MMPs  are  a  group  of  homogeneous  enzymes  that  de-
grade molecules of the extracellular matrix (ECM). They are 
grouped into collagenases, gelatinases, stromelysins, matrily- 
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sins, membrane type (MT)-MMPs and others basing on do-
main organization and substrate preference [45]. Gelatinase 
A  (MMP-2)  and  gelatinase  B  (MMP-9)  belong  to  the  ge-
latinases group. The MMPs contain several distinct domains 
that are responsible for secretion, latency, catalysis and sub-
strate recognition. All MMPs share one pre-domain and one 
catalytic  domain.  The  pre-domain  is  required  to  maintain 
latency of these enzymes and is cleaved off upon activation. 
The  following  catalytic  domain  contains  the  zinc-binding 
motif, with three conserved histidine residues which  com-
plex the critical metal ion and the catalytic domain contains 
additional zinc  and calcium  ions which maintain the three 
dimensional structure of MMPs and are necessary for stabil-
ity and enzymatic activities [9]. The gelatinases group con-
tains an additional three repetitional fibronectin type ǎ mo-
tifs inserted into the catalytic domain which suggests to fa-
cilitate the binding of these enzymes to their substrates gela-
tin and collagen [45]. In MMP-9, a unique linker sequence, 
which is more than 50 amino acids long, connects the active 
site and the hemopexin domain. It has been considered to be 
an independent protein domain that has low homology with 
type V collagen. The linkage domain is required to correctly 
orient the hemopexin domain for inhibition by TIMP-1 and 
internalization by LRP-1 and megalin. Therefore, the linkage 
and hemopexin domains down-regulate the bioavailability of 
active MMP-9. And interactions with the cargo receptors are 
proposed to be the original function of hemopexin domains 
[66]. The domain structure of MMP-9 is illustrated in Fig. 
(1A). MMP-9 are initially synthesized and secreted as inac-
tive zymogen pro-MMP-9 and activated by cleaving the pro-
domain so that most experiments about MMP-9 can detect 
two  forms  of  MMP-9:  one  at  about  92kDa,  which  corre-
sponded to pro-MMP-9, another at 88kDa, corresponding to 
an  activated  MMP-9.  MMP-9  has  proteolytic  activity  and 
degrade denatured collagens, gelatins and a number of ECM 
molecules including type ý, þ and Ą collagens, laminin 
and aggrecan core protein [45]. 
3. MMP-9 AND CEREBRAL ISCHEMIA 
  The  expressions  of  MMP-9  and  MMP-2  are  elevated 
after cerebral ischemia and able to open the BBB [50, 52]. In 270    Current Neuropharmacology, 2009, Vol. 7, No. 4  Dong et al. 
rodent models, MMP-9 responses appear to dominate in the 
acute phase, whereas MMP-2 elevations seem to occur in the 
delayed phase, days after stroke [50]. Moreover, recent data 
confirm the presence of high MMP-9 levels not only in in-
farct tissue but also in the peri-infarct areas, suggesting that 
MMP-9 involve in the process of infarct growth [55]. Fur-
thermore,  MMP-9 level seems  to peak within infarcts  that 
undergo hemorrhagic conversion, correlating with enhanced 
erythrocyte  extravasation  and  neutrophil  infiltration  sur-
rounding the affected capillaries together with severe colla-
gen IV degradation in the basal lamina [53]. Although in the 
brain,  gelatinases  have  been  the  most  intensively  studied 
because  of  the  ease  with  which  they  can  be  identified  by 
gelatin zymography and their prominent role in injury and 
repair [57], other MMP members may play important roles 
as  well  [54].  For  example,  MMP-3  can  be  activated  after 
ischemia-reperfusion in rat brain, causing the cleavage of the 
cerebral matrix agrin and contribute to BBB opening during 
neuroinflammation  after  intracerebral  lipopolysaccharide 
(LPS) injection in mice [23, 60]. Whatever, in this article we 
just focus on MMP-9 in cerebral ischemia. 
3.1. MMP-9 and Blood-Brain Barrier Opening 
  Blood-brain  barrier  (BBB)  plays  an  important  role  in 
protecting the neuronal microenvironment. Endothelial cells 
of brain capillaries have tight junctions, which can restrict 
molecules from moving between the blood and brain. The 
extracellular  matrix  molecules  constitute  the  basal  lamina 
which  is  around  the  capillary  with  pericytes.  MMP-9  can 
degrade  a  number  of  extracellular  matrix  molecules  to 
breakdown the BBB. When the integrity of BBB is lost, in-
flammatory cells and fluid penetrate the brain, causing hem-
orrhage, vesogenic edema and neuronal cell death. 
  A lot of studies have shown that the expression of MMP-
9 increases after permanent middle cerebral artery occlusion 
(pMCAO)  and  transient  middle  cerebral  artery  occlusion 
(tMCAO). Significant MMP-9 activity was observed at 12 
hours and reached maximum levels by 24 hours, then per-
sisted for 5 days at this level and returned to basal (zero) 
levels by 15 days using a  model of pMCAO in rats [52]. 
Also  a  finding  demonstrated  pro-MMP-9  expression  was 
significantly  increased  in  ischemic  regions  compared  with 
corresponding contralateral regions after 2 hours of ischemia 
and remained elevated until 24 hours and activated MMP-9 
was observed 4 hours after ischemia. Moreover, at the same 
time as the appearance of activated MMP-9, a clear increase 
of  BBB  permeability  was  detected.  This  suggested  that 
MMP-9 may play an active role in early vasogenic edema 
development after  stroke [18].  The  study with 50 minutes 
tMCAO rats showed an increase of MMP-9 from 4 hours to 
4 days after reperfusion [50]. In rats with 2 hours tMCAO, a 
maximally increase in MMP-9 was associated with maximal 
brain sucrose uptake at 48 hours of reperfusion [58]. There is 
the  discrepancy  among  these  studies  and  this  can  be  ex-
plained  by  technical  differences  or  different  animals  and 
different testing time phase. Recently, a research showed a 
strong  neutrophil  infiltration  in  the  infarcted  and  hemor-
rhagic areas with local high MMP-9 content closely related 
to  basal  lamina  collagen  IV  degradation  and  blood-brain 
barrier breakdown [54]. 
3.2. MMP-9 and Cerebral Infarction 
  Brain  injury  after  middle  cerebral  artery  occlusion 
(MCAO) is primarily a result of the decrease in blood flow 
and energy depletion. Then the loss of oxygen and glucose 
result in the neuronal cell death within minutes in the core 
zone, an area of severe ischemia. The ischemic penumbra, 
the hypoperfusion region associated with the focal ischemia, 
is variable. This area can be recovery or become infarction 
after reperfusion.  
  Recently,  some  studies  showed  that  the  activation  of 
MMP-9  relate  to  the  infarct  size.  Pro-MMP-9  levels  in 
plasma  and  activated  MMP-9  levels
  in  brain  homogenates 
were
  progressively  increased  over  the  course  of  24  hours 
after  permanent  middle
  cerebral  artery  occlusion  in  male 
Sprague-Dawley rats. And plasma levels of pro-MMP-9 at 
24 hours
 were correlated with final infarct volumes [48].A 
decrease in infarct size after focal ischemic insult in rats was 
observed when a MMP-9 neutralizing monoclonal antibody 
was administered [52]. Serial MMP-9 and MMP-2 in 39 pa-
tients  with  cardioembolic  stroke  were  determined.  Results 
suggested  that  higher  MMP-9  levels  were  associated  with 
neurological  deterioration  during  the  first  48  hours  and  a 
positive  correlation  was  between  mean  MMP-9  and  total 
infarct volume [40]. Several inflammatory families such as 
proinflammatory  cytokines  (TNF-α,  IL-6),  adhesion  mole-
cules (ICAM-1), chemokines (IL-8), or matrix metalloprote-
inases (MMP-2, MMP-9) of 16 patients with acute middle 
cerebral  artery stroke were  studied.  Among them,  MMP-9 
was found to be the most powerful and only predictor of the 
infarct volume measured  as a diffusion-weighted  magnetic 
resonance imaging lesion [43]. The serum levels of MMP-2, 
MMP-3, MMP-9, MMP-13, TIMP-1, TIMP-2 and laminin in 
50 patients with acute ischemic stroke were measured and 
results demonstrated that levels of MMP-9 and laminin var-
ied significantly by infarct size [26]. These studies certified 
the increased of MMP-9 in infracted tissue both in animal 
experiments and human stroke. Thus, MMP-9 can be a po-
tential therapeutic target for the treatment of stroke. 
3.3. MMP-9 and Hemorrhagic Transformation 
  Plasminogen  activators,  including  tissue  plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA), 
are serine proteases that activate plasminogen into plasmin. 
Recombinant  tPA  (rtPA)  is  beneficial  in  ischemic  stroke 
when  thrombolytic  therapy  is  started  within  3  hours  after 
symptom onset. On the other hand, thrombolysis is associ-
ated with the risk of hemorrhage transformation.  
  A lot of studies about the relationships between tPA and 
MMPs show that the plasminogen-plasmin system might be 
involved in activation of MMPs. Administration of heparin 
for 3 hours after MCAO increased tPA and MMP-9 activity 
and their mRNA expression in wild-type mice but not in tPA 
deficient  knockout  mice  [72].  Closure  of  the  BBB  with 
broad-spectrum  MMP  inhibitor  BB-94  given  before  rtPA 
treatment reduced rtPA-mediated mortality in 6/12 to 33% 
[49]. Recently, a study demonstrated for the first time that 
the injection of a MMP inhibitor for 3 hours after the ische-
mia in rats significantly decreased the brain edema and re-
duced  the  risk  of  hemorrhagic  transformation  after  throm- 
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bolysis  with  rtPA  [11].  A  study  published  in  2001  firstly 
showed an association between MMP-9 expression and sev-
eral  subtypes  of  hemorrhagic  transformation  after  human 
cardioembolic  stroke  [41].  Subsequently,  a  study  demon-
strated that high plasma levels of MMP-9 are independently 
associated  with  hemorrhagic  transformation  in  acute 
ischemic stroke by studying 38 patients [8]. Moreover, the 
baseline  MMP-9  level  was  the  only  factor  independently 
associated with late hemorrhagic infarction among patients 
they  observed  [41].  Therefore,  the  baseline  MMP-9  level 
predicts  parenchymal  hemorrhagic  appearance  after  t-PA 
treatment [42]. The findings above suggest that the endoge-
nous  tPA  or  rtPA  treatment,  through  the  enhancement  of 
MMP-9 expression, play an important role in hemorrhagic 
transformation after cerebral ischemia. MMP inhibitors can 
be used before thrombolytic therapy to reduce hemorrhagic 
transformation. 
3.4. MMP-9 and Stroke Recovery 
  MMP-9 promotes injury of the BBB, vasogenic edema 
formation, infarct size and hemorrhagic transformation in the 
acute phase after cerebral ischemia. But MMP-9 may have a 
different role during delayed phases after stroke. MMP-9 is 
upregulated in peri-infarct cortex at 7–14 days after stroke 
and is colocalized with markers of neurovascular remodel-
ing. Treatment with MMP inhibitors at 7 days after stroke 
suppresses  neurovascular  remodeling,  increases  ischemic 
brain injury and impairs functional recovery at 14 days [74]. 
MMP-9 also mediate neuroblast cells from the subventricu-
lar zone expand and migrate toward damaged tissue during 
the  2  week  recovery  period  after  transient  focal  cerebral 
ischemia in mice. And inhibitors of MMPs suppress neuro-
genic migration from subventricular zone into the striatum 
[31,  73].  These  data  suggest  that  MMP-9  are  involved  in 
endogenous  mechanisms  of  neurovascular  remodeling  in 
peri-infarct cortex as the brain seeks to heal itself after in-
jury. 
4. THE REGULATION OF MMP-9 AND THERAPEU-
TIC IMPLICATION  
4.1. The Expression and Regulation of MMP-9  
  The promoter sequence of MMP-9 contains AP-1 binding 
site  at  approximatally  -80bp  and  NF-κB  binding  site  at  -
600bp [9]. The transcription of MMP-9 is a complex, tight 
and regulated process [36]. A lot of studies have proved that 
some  inflammatory  cytokines  and  growth  factors,  such  as 
IL-1β,  TNF-α,  FGF,  EGF  can  stimulate  the  secretion  of 
MMP-9  [14,  33,  51,  62].  Inflammatory  cells,  including 
monocytes, macrophages and leukocytes are the major origi-
nator of MMP-9 in many pathological conditions [4, 12, 25, 
61]. In recent years, some researchers focused on the cellular 
sources of MMP-9 responsible for vascular and parenchymal 
injury after focal stroke. A research implicated leukocytes, 
most likely neutrophils, as a key cellular source of MMP-9, 
which, in turn, promotes leukocyte recruitment, causes BBB 
breakdown and neuronal  injury after transient focal stroke 
using MMP-9
-/- mice and chimeric knockouts lacking either 
MMP-9 in leukocytes or in resident brain cells [19]. Another 
study using bone marrow chimeric mice with MMP-9 null 
and wild-type as donor and recipient demonstrated that bone 
marrow-derived cells are the major source of MMP-9 in the 
ischemic  brain  and  BMDC-derived  MMP-9  contributes  to 
BBB dysfunction [67]. The inflammatory factors stimulate 
the  secretion  of  MMP-9  by  activating  the  signalling  path-
ways  including  MEK1-Erk,  P38,  PI3K-Akt.  At  last,  these 
protein kinases regulate the transcription of MMP-9 through 
activating AP-1 and NF-κB, which subsequently bind to cis 
elements on the promoter. This promotes the further recruit-
ment of chromatin remodeling complexes, co-activators and 
general transcriptional machinery to induce MMP-9 expres-
sion [36]. At least three classes of co-activators are essential 
for MMP-9 expression, including CBP/P300, PCAF, CARM1 
and GRIP1 [75]. However, not all of  the  co-activators in-
volved in MMP-9 expression are clear. 
  MMP-9 are synthesized and secreted into extracellular as 
inactive zymogen pro-MMP-9. Pro-MMP-9 is activated by 
disruption of the zinc-thio interaction between the catalytic 
site and the pro-domain [5]. Plasmin, tPA and uPA are all 
involved  in  the  process  of  MMPs  activation  and  plasmin, 
MMP-2,  MMP-3,  MMP-13  can  activate  the  pro-MMP-9 
directly [9]. In addition, pro-MMP-9 can be activated by NO 
via s-nitrosylation of MMP-9 protein [21, 39]. MMP-9 can 
be  inhibited  by  all  tissue  inhibitors  of  metalloproteinase 
(TIMP-1, TIMP-2, TIMP-3 and TIMP-4) with a preference of 
TIMP-1. TIMP-1 can form a complex with pro-MMP-9 in-
teracted with MMP-3 and then dissociated into free pro-MMP-
9 and TIMP-1- MMP-3 complex [13]. The process of MMP-
9 expression and regulation is summarized in Fig. (1B). 
4.2. Therapeutic Implication 
  Under the physiological conditions, transcriptional regu-
lation, zymogen activation and endogenous inhibitors could 
control MMP-9 activity. However, this physiological balance 
is  disturbed  after  cerebral  ischemia.  An  overexpression  of 
MMP-9  accelerates  matrix  degradation,  disrupts  the  BBB 
and relates to hemorrhagic transformation  either  in animal 
models or human patients. Since the expression process and 
the  regulation  mechanism  of  MMP-9  have  already  been 
known,  some  therapeutics  for  cerebral  ischemia  could  be 
available  by  regulating t he  expression  and  activation  of 
MMP-9.  Beside  natural  MMP  inhibitors,  treatment  with 
MMP  monoclonal  antibodies  [52],  genetic  approaches  [2] 
and the broad-spectrum MMP inhibitors such as BB-94 [1, 
49], KB-R7785 [29] have been proved to reduce ischemic 
damage in numerous experimental settings.  
  Moreover, many drugs or substances have been proven to 
attenuate the elevated levels of MMP-9 after ischemia and 
reduce the damage of cerebral ischemic.  
4.2.1. Tetracycline Derivatives 
  Minocycline inhibits enzymatic activity of gelatin prote-
ases activated by ischemia after experimental stroke and is 
likely to be selective for MMP-9 at low doses [37]. Mino-
cycline given to rats twice daily (30mg/kg bodyweight) can 
reduce  infarct  sizes,  volume  and  signal  intensity  of  BBB 
breakdown and improve neuroscore, which was most likely 
due to inhibition of MMP-2 and MMP-9 [46]. Doxycycline 
signiﬁcantly  inhibited  MMP-9  activity  in  gel  zymography 
and also suppressed in situ gelatinase activity and reduced 
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to mice 30 min before and 2 h after ischemia [30]. By inhib-
iting MMP-2, MMP-9 and plasminogen activators, Doxycy-
cline  is  shown  to  decrease  injury  volumes  and  protects 
against damage of the microvessels in focal cerebral ische-
mia in rats [3]. As described above, tetracycline and tetracy-
cline derivatives have been proved to reduce infarct  sizes, 
protect BBB and have neuroprotective  effect in models of 
cerebral ischemia. They are potential therapeutic agents for 
acute treatment of cerebral ischemic. 
4.2.2. ACE Inhibitors (ACEI) and AT1 Receptor Blockers 
  Following cerebral ischemia, angiotensin II (venous infu-
sion)  increases  cerebral  edema  and  mortality  by  inducing 
MMP-9 expression in vascular smooth muscle cell through 
angiotensin  type  1  (AT1)  receptor  and  NF-κB  pathways  
[22, 27]. ACEI and AT1 receptor blockers can reduce MMP-
9 expression and improve ischemic injury after focal cerebral 
ischemia.  
  Olmesartan, a AT1 receptor blocker can reduce the reac-
tive upregulation in brain  angiotensin II,  MMP-2,  MMP-9 
and membrane type 1-MMP in the ischemic area to improve 
stroke  index  score,  infarct  volume,  and  cerebral  edema  in 
cerebral  ischemia  model.  In  particular,  stroke  index  score, 
infarct volume, and cerebral edema were reduced even with 
a low dose of olmesartan that did not decrease blood pres-
sure [28]. In another study, twelve spontaneously hyperten-
sive stroke-prone rats were randomized into two groups and 
each group was treated with either an antihypertensive dose 
of  ramipril  (an  ACE  inhibitor)  or  placebo  for  6  months. 
MMP-9  expression  significantly  decreased  by  37%  in  the 
cortex and by 25% in the basal ganglia in animals treated 
with ramipril [32]. Trandolapril (an ACEI, 5 mg/kg per day) 
administered  orally  for  7  days  before  permanently  middle 
cerebral  artery  occlusion  suppressed  MMP-2  and  MMP-9 
activities at 1 day after MCAO [63].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A) The domain structure of MMP-9. S – signal peptide; C – catalytic domain; F – fibronectin type II domain; L – linkage domain; 
HP – hemopexin like domain. (B) Schematic drawing to show the process of MMP-9 expression and regulation. Akt – Protein kinase B 
(PKB); ECM – extracellular matrix; MMP – matrix metalloproteinase; PI3K – phosphatidylinositol 3-kinase; Polû – RNA polymerase II;
TIMP – tissue inhibitor of metalloproteinase; uPA – urokinase type plasminogen activator; tPA – tissue type plasminogen activator; ERK – 
extracellular signal activated protein kinase; MEK – mitogen activated ERK activating kinase; NO – nitric oxide. Boxes in nucleus indicate 
the following cis elements: AP-1 – activator protein-1; PEA3 – polyoma enhancer A binding protein-3; GC – Sp-1 binding site; NF-κB – 
nuclear factor κB; TATA – TATA box. 
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4.2.3. Cyclooxygenase Inhibitors 
  It has long been recognized that the metabolism of ara-
chidonic  acid  via  cyclooxygenase  (COX)  isozymes  is  an 
important  contributor  to  the  neuroinflammatory  processes 
following cerebral ischemia. In particular, cyclooxygenase-2 
(COX-2) has been shown to be a key player in the evolution 
of ischemic brain injury [6]. 
  Recent  experimental  evidences  suggest  that  some  non-
steroidal anti-inflammatory drugs have therapeutic potential 
in the treatment of patients with brain ischemia. Indometha-
cin, an inhibitor of COX-1 and COX-2, significantly reduced 
the  expression  and  activity  of  MMP-9  as  assessed  by  im-
munoblotting and gelatin-substrate  zymography, attenuated 
the  brain  edema  [7].  Treatment  with  nimesulide  markedly 
attenuates  the  number  of  neurons  and  endothelial  cells 
positive for MMP-2 and MMP-9 [6, 68]. Aspirin, a typical 
inhibitor of COX, has been proved to inhibit MMP-9 expres-
sion [44].  
  Estrogen has shown to suppress COX-2 expression and 
function induced by interleukin-1β, indicating that estrogen 
could protect BBB disruption through its inhibition on COX-
2  [47].  Estrogens  could  also  attenuate  BBB  disruption  in-
duced by transient cerebral ischemia by inhibition of MMP-2 
and MMP-9 activation. This suggests an important role of 
estrogens as multiple targeting protectants against ischemic 
stroke on cellular as well as vascular components of central 
nervous system [34].  
4.2.4. Antioxidants 
  Resveratrol, a polyphenolic antioxidant, has neuroprotec-
tive activity against cerebral ischemia. The elevated levels of 
MMP-9  were  significantly  attenuated  in  the  resveratrol-
treated mice as compared to the vehicle MCAO mice sug-
gests  that  resveratrol  has  protective  effects  against  acute 
ischemic  stroke  which  could  be  attributed  to  its  property 
against  MMP-9  by  inhibiting  JNK  and  PKC  signal  trans-
duction [17, 69].  
  Crocin is the most abundant component with antioxidant 
effects  among  the  constituents  of  saffron.  Crocin  inhibits 
MMP-9 expression in cortical microvessels in mice with 20 
min of bilateral common carotid artery occlusion followed 
by 24h of reperfusion. Furthermore, it markedly inhibits oxi-
dizing reactions, modulates the ultrastructure of cortical mi-
crovascular  endothelial  cells,  inhibits  GRK2  translocation 
from  the  cytosol  to  the  membrane  and  reduces  ERK1/2 
phosphorylation. So, crocin protects the brain against exces-
sive oxidative stress and constitutes a potential therapeutic 
candidate in transient global cerebral ischemia [76].  
  Quercetin, a natural flavonoid, which is a strong antioxi-
dant and radical scavenger, protects various tissues including 
neural tissue from ischemia and reperfusion-induced injury 
by inhibiting MMP-9 activity [10]. 
4.2.5. Other Drugs and Substances 
  Some other drugs showed the potential protective effects 
on  cerebral  ischemia  by  downregulating  the  expression  of 
MMP-9. Calpains and cathepsins are 2 families of cysteine 
proteases. Recent evidences suggested that calpain/ cathepsin 
B and MMP-9 are interlinked. E64d, a calpain/cathepsin B 
inhibitor  has  been  shown  to  prevent  activation  of  MMP-9 
after focal cerebral ischemia and reperfusion injury [64].  
  The post-ischemic MMP-9 overexpression could be regu-
lated by poly (ADP-ribose) polymerase (PARP). The anti-
hemorrhagic  effect  of  PJ34,  a  potent  PARP  inhibitor  was 
associated with a 57% decrease in  MMP-9 overexpression 
[24].  
  Atorvastatin, an antiatherosclerosis drug, lowers plasma 
MMP-9 in patients with acute coronary syndrome [20, 65, 
70]. Glucocorticoid increases TIMP-1 in the brain endothe-
lial cell line cEND to reduce the levels of MMP-9 [16].  
CONCLUSION  
  MMP-9 provides a new approach for human stroke ther-
apy. The regulations for MMP-9 both on gene level and pro-
tein  level  have  been  known.  So  the  potential  compounds 
decrease MMP-9 expression by blocking signal pathways or 
inhibit its activation should be exploited. And knowledge of 
the three-dimensional (3D) structure of MMPs could provide 
valuable insights into the structural determinants of selective 
inhibition of a particular MMP [59]. Further studies about 
the  pathways  for  MMP-9  expression  both  in  normal  and 
pathological condition are still needed. Moreover, the con-
crete  interaction  mechanism  between  drugs  and  MMP-9 
needs to be further explored. However, MMP-9 has biphasic 
roles in stroke pathophysiology. It mediates injury during the 
acute phase and contributes to neurovascular remodeling in 
the penumbra during the recovery phase. Future investiga-
tions should dissect where, when and how MMP-9 increase 
in damaged brain makes the transition from injury into repair 
[35].  As  more  information  about  MMP-9  we  know,  anti-
MMP-9  therapy  for  cerebral  ischemia  could  be  designed 
more rationally.  
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